2 results
Approved WMOPending
The primary objective is to characterize the change in the Pharmacodynamic (PD) biomarker, fecal calprotectin, during treatment with anrukinzumab.The secondary objectives include:* Characterization of the PK profile and total IL-13 of three multiple…
Approved WMORecruiting
Our primary objective is to assess the effect of diltiazem on coronary microvascular function as assessed by coronary reactivity testing in symptomatic patients with CMD.